Missions

The Pfizer-led Physical Activity Harmonization Mission Has Launched!

Team DEEP Measures — Tue, 28 Jul 2026 10:01:00 GMT

Originally published 5 March 2026 · Updated 27 July 2026.
The Physical Activity Harmonization Mission is officially underway, having kicked off in late June. This Pfizer-led consortium, in partnership with DEEP Measures, includes four pharmaceutical companies, one academic institution, and one clinical technology provider, bringing multiple perspectives to the table from day one. The mission aims to establish cross-industry consensus on terminology and definitions for measures of physical activity, creating a shared scientific foundation that accelerates innovation, evidence generation, and regulatory alignment.

Digital Measures for Respiratory Conditions: A Pre-competitive Mission for COPD and Non-CF Bronchiectasis

Team DEEP Measures — Thu, 14 May 2026 13:48:26 GMT

This DEEP Measures-led precompetitive mission seeks to align industry stakeholders on regulatory-ready digital measures for respiratory conditions, beginning with COPD and non-CF bronchiectasis, creating a shared scientific foundation that accelerates evidence generation and regulatory engagement.

Unifying Digital Measures in Parkinson's Disease

Team DEEP Measures — Wed, 18 Feb 2026 08:07:30 GMT

Building Digital Measures for PD? DEEP can help!

Clinical trials in PD have relied on snapshot, clinic-based assessments for too long. We're changing that: bringing pharma, biotech, researchers, patients, and tech vendors together to build validated, regulatory-ready digital endpoints for Parkinson's.

Defining New Digital Measures in Myasthenia Gravis

Team DEEP Measures — Wed, 21 Jan 2026 11:46:45 GMT

Developing precise and comprehensive digital measures for Myasthenia Gravis (MG) that capture meaningful aspects of the disease and address unmet needs in patient care and drug development.

DEEP/NICE Advice pilot mission: The way medicines reach European patients has changed - the time to prepare is now!

Team DEEP Measures — Tue, 20 Jan 2026 17:05:42 GMT

Why this matters now ?

Authorities increasingly want exactly what digital measures are built to deliver: continuous, patient-relevant outcomes from wearables, sensors and apps. At the same time, the rules for how Europe assesses that evidence have changed. Since January 2025, every new cancer medicine and advanced therapy entering the EU is subject to a Joint Clinical Assessment (JCA): the EU now runs the clinical comparison once, centrally, for all member states. The remit widens from here - high-risk devices from 2026, orphan medicines from 2028, all remaining medicines from 2030.

Read those dates carefully. They are when JCA applies at launch, but the evidence is designed years earlier, in the trials running now. Every clinical programme beyond Phase 1 today is already affected. The time to build evidence that meets these expectations is now, not at submission.